Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OSE Immunotherapeutics
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
September 23, 2026
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
September 9, 2026
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
August 28, 2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
May 27, 2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
May 23, 2026
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
May 23, 2026
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
May 22, 2026
OSE Immunotherapeutics Evolves its Leadership Team
May 21, 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
May 16, 2026